AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00375934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsule, every 6 hours
Trial: NCT02980835
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate B contains 10 mL of 0.9% normal saline.
Trial: NCT02980835
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate C contains 0.125 mL of epinephrine-1:1000 preparation.
Trial: NCT01266148
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
Trial: NCT02625519
Drug: Urinary follicle-stimulating hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian stimulation with highly purified urinary follicle-stimulating hormone
Trial: NCT02135640
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution
Trial: NCT04646317
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% as placebo
Trial: NCT01677611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02901717
Drug: Antibiotic lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
Trial: NCT00744055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03191084
Drug: Placebo Marijuana
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
Trial: NCT03836287
Drug: Sofpironium Bromide Gel, 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT03836287
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel
Trial: NCT00002872
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03692910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-217 matching placebo capsule
Trial: NCT00318838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
Trial: NCT04689984
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin, pregabalin, or amitriptyline
Trial: NCT00151411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01028209
Drug: [18F] PBR06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]PBR06, followed by PET imaging.
Trial: NCT03351322
Drug: ENERGI-F701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENERGI-F701 are applied for treatment of hair loss.
Trial: NCT04094506
Drug: ASP1948
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT02606773
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid in different ways and doses
Trial: NCT02571361
Drug: Ibuprofen (400 mg x 4)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively
Trial: NCT02571361
Drug: Ibuprofen (200 mg x 4)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively
Trial: NCT02571361
Drug: Placebo (x4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given in 6 hour intervals the first 24 hours postoperatively
Trial: NCT04003155
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT00920465
Drug: mifegyne and cytotec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One day dosage versus two days dosage
Trial: NCT02874794
Drug: LCZ696 (sacubitril/valsartan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24/26mg, 49/51mg and 97/103mg oral, tablets.
Trial: NCT02874794
Drug: Placebo of LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
Trial: NCT00845910
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900mg/m2 po on days 1-14 of every 3 week cycle
Trial: NCT01272934
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical gel 1%-4 times daily
Trial: NCT03626753
Drug: Acetaminophen, (paracetamol) 500Mg Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours.
Trial: NCT03626753
Drug: (Acetaminophen paracetamol) IV Soln 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
Trial: NCT03626753
Drug: (Piroxicam piroxan) 20 MG Oral Tablet
RxNorm normalized name: piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 tablets of piroxicam (piroxan) administrated orally once per 24 hours.
Trial: NCT03626753
Drug: (Piroxicam piroxan) 20Mg/1mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours.
Trial: NCT03855189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray administered for 4 weeks.
Trial: NCT01978912
Drug: KTP-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KTP-001 is one time dose intradiscally.
Trial: NCT01687517
Drug: Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
Trial: NCT01334125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules once daily by mouth for 9 months
Trial: NCT00803634
Drug: Standard of Care IV antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
Trial: NCT01286259
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open label 500mg disulfiram per day by mouth for 14 days
Trial: NCT00661063
Drug: vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bid - 12 weeks
Trial: NCT03985319
Drug: YYD601 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)
Trial: NCT00688805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching capsule containing no active medication
Trial: NCT03578900
Drug: Citric Acid based Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00853450
Drug: AZD6482
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion during a maximum of 5 hours
Trial: NCT03710434
Drug: AZD4635 solid oral formulation - fasted
RxNorm normalized name: CORYDALIS SOLIDA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.
Trial: NCT03710434
Drug: AZD4635 solid oral formulation - fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.
Trial: NCT03710434
Drug: AZD4635 solid oral formulation variant 1 - fasted
RxNorm normalized name: CORYDALIS SOLIDA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.
Trial: NCT03710434
Drug: AZD4635 solid oral formulation variant 2 - fasted
RxNorm normalized name: CORYDALIS SOLIDA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
Trial: NCT03710434
Drug: [14C] AZD4635 IV microtracer - fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
Trial: NCT03174886
Drug: AADvac1 40 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active immunotherapy against neurofibrillary pathology.
Trial: NCT03174886
Drug: AADvac1 160 µg
RxNorm normalized name: immunoglobulin G, human 160 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active immunotherapy against neurofibrillary pathology.
Trial: NCT00966316
Drug: aspirin，chinese herbs；
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
Trial: NCT02516059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
Trial: NCT00766415
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, twice daily, 4 weeks treatment
Trial: NCT00766415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00023452
Drug: RPT + INH once weekly for 3 months given by DOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons \> 50.0 kg. For persons \< 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if \> 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old.~Therapy will be given by Directly Observed Therapy (DOT).
Trial: NCT04091841
Drug: protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three sachet of protein supplement to be mixed in with water used daily.
Trial: NCT02528292
Drug: Anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
Trial: NCT01358526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match OXN taken orally every 12 hours
Trial: NCT02439346
Drug: BAY1143269 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
Trial: NCT03832946
Drug: GB0139
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.
Trial: NCT03832946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered as inhalation once a day
Trial: NCT01462344
Drug: ADVAIR 100/50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
Trial: NCT01462344
Drug: ADVAIR 250/50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
Trial: NCT00928148
Drug: SPD465
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 or 75 mg once daily for 7 days
Trial: NCT00928148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 7 days
Trial: NCT00955877
Drug: Control: Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
Trial: NCT03394924
Drug: EDP-305 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets daily for 12 weeks
Trial: NCT03394924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets daily for 12 weeks
Trial: NCT01702129
Drug: anti-EGFR immunoliposomes loaded with doxorubicin
RxNorm normalized name: Anti-egfr/c-met bispecific antibody emb-01
DrugBank: EMB-01 (DB16091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
Trial: NCT03510481
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
Trial: NCT03510481
Drug: artemether 20mg/lumefantrine 120mg (AL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
Trial: NCT03283670
Drug: Placebo Gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
Trial: NCT04159831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT01235039
Drug: VIAject®25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
Trial: NCT01235039
Drug: VIAject®7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
Trial: NCT03177993
Drug: 3 drug dose - IDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies
Trial: NCT01418300
Drug: sequential versus triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
Trial: NCT03890302
Drug: FB704A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT03890302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
Trial: NCT00206674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
Trial: NCT03136068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-abdominal injection
Trial: NCT01071395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill given 3 times daily
Trial: NCT02766608
Drug: BFF MDI 320/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded Treatment
Trial: NCT02766608
Drug: BFF MDI 160/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded Treatment
Trial: NCT02766608
Drug: FF MDI 9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded Treatment
Trial: NCT02766608
Drug: Symbicort® TBH 400/12 μg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open Label
Trial: NCT02343458
Drug: GP MDI (PT001)
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Trial: NCT02343458
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
Trial: NCT02326103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01610700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each actuation of placebo delivered the excipients only.
Trial: NCT01405391
Drug: PM01183
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
Trial: NCT02401256
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.
Trial: NCT00359112
Drug: sulphonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03811912
Drug: CTP-543 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as tablets to aid treatment masking.
Trial: NCT01156753
Drug: Investigator's Choice chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
Trial: NCT01782131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
Trial: NCT04367168
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
Trial: NCT01346657
Drug: Nifidipine & LipoCol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.